share_log

Beam Therapeutics analyst ratings

Beam Therapeutics analyst ratings

BEAM治疗公司分析师评级
Benzinga Analyst Ratings ·  2022/05/09 13:14
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
05/09/2022 250.22% SVB Leerink $118 → $121 Maintains Outperform
04/28/2022 79.45% Credit Suisse → $62 Initiates Coverage On → Neutral
01/10/2022 250.22% SVB Leerink $116 → $121 Maintains Outperform
01/05/2022 276.27% Guggenheim → $130 Initiates Coverage On → Buy
11/09/2021 235.75% SVB Leerink $117 → $116 Maintains Outperform
10/19/2021 238.64% SVB Leerink → $117 Initiates Coverage On → Outperform
09/10/2021 334.15% B of A Securities → $150 Initiates Coverage On → Buy
06/29/2021 331.26% Wedbush $114 → $149 Maintains Outperform
05/11/2021 — Redburn Partners Initiates Coverage On → Buy
05/04/2021 146.02% RBC Capital → $85 Initiates Coverage On → Sector Perform
03/01/2021 160.49% Barclays $47 → $90 Downgrades Overweight → Equal-Weight
02/16/2021 319.68% Wells Fargo → $145 Initiates Coverage On → Overweight
01/29/2021 189.44% JP Morgan $38 → $100 Downgrades Overweight → Neutral
01/06/2021 143.13% Stifel → $84 Initiates Coverage On → Hold
08/05/2020 -4.49% William Blair → $33 Initiates Coverage On → Outperform
03/02/2020 -7.38% Wedbush → $32 Initiates Coverage On → Outperform
03/02/2020 -7.38% Barclays → $32 Initiates Coverage On → Overweight
03/02/2020 -7.38% Jefferies → $32 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
05/09/2022 250.22% SVB Leerink $118 → $121 维护 跑赢大盘
04/28/2022 79.45% 瑞士信贷 → $62 开始承保 →中性
01/10/2022 250.22% SVB Leerink $116 → $121 维护 跑赢大盘
01/05/2022 276.27% 古根海姆 → $130 开始承保 →购买
11/09/2021 235.75% SVB Leerink $117 → $116 维护 跑赢大盘
10/19/2021 238.64% SVB Leerink → $117 开始承保 →跑赢大盘
09/10/2021 334.15% B of A证券 → $150 开始承保 →购买
06/29/2021 331.26% 韦德布什 $114 → $149 维护 跑赢大盘
05/11/2021 — Redburn合作伙伴 开始承保 →购买
05/04/2021 146.02% 加拿大皇家银行资本 → $85 开始承保 →行业表现
03/01/2021 160.49% 巴克莱 $47 → $90 评级下调 超重→等重
02/16/2021 319.68% 富国银行(Wells Fargo) → $145 开始承保 →超重
01/29/2021 189.44% 摩根大通 $38 → $100 评级下调 超重→中性
01/06/2021 143.13% Stifel → $84 开始承保 →保留
08/05/2020 -4.49% 威廉·布莱尔 → $33 开始承保 →跑赢大盘
03/02/2020 -7.38% 韦德布什 → $32 开始承保 →跑赢大盘
03/02/2020 -7.38% 巴克莱 → $32 开始承保 →超重
03/02/2020 -7.38% 杰富瑞 → $32 开始承保 →购买
Data brought to you by Benzinga APIs
Benzinga API为您带来的数据

Beam Therapeutics Questions & Answers

BEAM治疗学问答

What is the target price for Beam Therapeutics (BEAM)?
BEAM治疗(BEAM)的目标价格是多少？

The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by SVB Leerink on May 9, 2022. The analyst firm set a price target for $121.00 expecting BEAM to rise to within 12 months (a possible 250.22% upside). 9 analyst firms have reported ratings in the last year.

BEAM治疗公司(纳斯达克代码：BEAM)的最新目标价是由SVB Leerink于2022年5月9日报道的。这家分析公司将目标价定为121.00美元，预计BEAM将在12个月内上涨至250.22美元(可能上涨250.22%)。去年有9家分析公司公布了评级。

What is the most recent analyst rating for Beam Therapeutics (BEAM)?
光束治疗公司(BEAM)的最新分析师评级是什么？

The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by SVB Leerink, and Beam Therapeutics maintained their outperform rating.

比姆治疗公司(纳斯达克代码：BEAM)的最新分析师评级由SVB Leerink提供，比姆治疗公司维持其表现优于大盘的评级。

When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?
束流疗法(BEAM)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on May 9, 2022 so you should expect the next rating to be made available sometime around May 9, 2023.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与比姆治疗公司的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。BEAM治疗公司的上一次评级是在2022年5月9日提交的，所以你应该预计下一次评级将在2023年5月9日左右提供。

Is the Analyst Rating Beam Therapeutics (BEAM) correct?
分析师对光束治疗公司(BEAM)的评级正确吗？

While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a maintained with a price target of $118.00 to $121.00. The current price Beam Therapeutics (BEAM) is trading at is $34.55, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的光束治疗公司(BEAM)评级保持不变，目标价在118.00美元至121.00美元之间。BEAM目前的交易价格为34.55美元，超出了分析师的预测范围。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发